睿知中国医院研究地图
候选清单

正在招募肺癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Adjuvant Benmelstobart for Stage IB, Grade 3 Invasive Lung Adenocarcinoma

ClinicalTrials.gov 上登记的一项肺癌开放试验,由上海市肺科医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方上海市肺科医院Shanghai Pulmonary Hospital上海医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06528847,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 6

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(6 项)收起清单
  1. 18 岁 至 74 岁;性别:不限

    登记记录的入选字段

  2. Pathologically confirmed stage IB (AJCC TNM staging, 8th edition) lung adenocarcinoma;

    入选标准第 3 条

    Pathologically diagnosed as grade 3 invasive lung adenocarcinoma according to the 2020 grading system proposed by the International Association for the Study of Lung Cancer (IASLC) Pathology Committee (poorly differentiated: any tumor with 20% or more of high-grade patterns, including solid, micropapillary, and/or complex glandular patterns);

    入选标准第 5 条

  3. Achieved complete resection (R0) after lobectomy, bilobectomy, or sleeve resection;

    入选标准第 4 条

    Patients are screened and enrolled within 4 to 12 weeks after surgery;

    入选标准第 10 条

    For female participants of childbearing potential, a negative serum pregnancy test must be obtained within 7 days prior to the first dose of the study drug;

    入选标准第 12 条

    Major organ functions must be normal within 7 days prior to the first dose of the study drug.

    入选标准第 14 条

    Currently participating in an interventional clinical trial, or having received other investigational drugs or used investigational devices within 4 weeks prior to the first dose of the study drug;

    排除标准第 3 条

    Systemic corticosteroids or immunosuppressants must have been administered continuously for 7 days within 14 days prior to the first dose of the study drug;

    排除标准第 4 条

    Presence of other malignant tumors within 5 years prior to the first dose of the study drug;

    排除标准第 8 条

  4. Performance status score of 0 or 1 (Eastern Cooperative Oncology Group (ECOG) performance status scale);

    入选标准第 11 条

  5. No active EGFR mutations (including but not limited to exon 19 deletions, exon 21 L858R, exon 21 L861Q, exon 18 G719X, or exon 20 S768I mutations) or ALK rearrangements;

    入选标准第 8 条

  6. Female participants of childbearing potential or male participants with partners of childbearing potential must agree to use highly effective contraception (with an annual failure rate of less than 1%) starting from 7 days before the first dose of the study drug and continuing until 24 weeks after the last dose;

    入选标准第 13 条

    Pregnant and/or breastfeeding women;

    排除标准第 13 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);影像与可测量病灶;试验排除的其他疾病。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06528847,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Participants are able to understand the informed consent form, voluntarily agree to participate, and sign the informed consent form;
  2. Participants must be 18 years or older and under 75 years of age on the day they sign the informed consent form;
  3. Pathologically confirmed stage IB (AJCC TNM staging, 8th edition) lung adenocarcinoma;
  4. Achieved complete resection (R0) after lobectomy, bilobectomy, or sleeve resection;
  5. Pathologically diagnosed as grade 3 invasive lung adenocarcinoma according to the 2020 grading system proposed by the International Association for the Study of Lung Cancer (IASLC) Pathology Committee (poorly differentiated: any tumor with 20% or more of high-grade patterns, including solid, micropapillary, and/or complex glandular patterns);
  6. No prior receipt of any anti-tumor treatment, including but not limited to systemic chemotherapy, immunotherapy, or radiotherapy;
  7. Expected survival time more than 12 weeks;
  8. No active EGFR mutations (including but not limited to exon 19 deletions, exon 21 L858R, exon 21 L861Q, exon 18 G719X, or exon 20 S768I mutations) or ALK rearrangements;
  9. Tumor PD-L1 expression ≥1% (the PD-L1 IHC 22C3 pharmDx reagent, antibody clone number: 22C3, detection platform: DAKO Autostainer Link 48);
  10. Patients are screened and enrolled within 4 to 12 weeks after surgery;
  11. Performance status score of 0 or 1 (Eastern Cooperative Oncology Group (ECOG) performance status scale);
  12. For female participants of childbearing potential, a negative serum pregnancy test must be obtained within 7 days prior to the first dose of the study drug;
  13. Female participants of childbearing potential or male participants with partners of childbearing potential must agree to use highly effective contraception (with an annual failure rate of less than 1%) starting from 7 days before the first dose of the study drug and continuing until 24 weeks after the last dose;
  14. Major organ functions must be normal within 7 days prior to the first dose of the study drug.

排除标准:Exclusion Criteria:

  1. Postoperative pathological diagnosis of mixed histological features;
  2. Incomplete resection (R1/R2) or wedge resection, segmentectomy;
  3. Currently participating in an interventional clinical trial, or having received other investigational drugs or used investigational devices within 4 weeks prior to the first dose of the study drug;
  4. Systemic corticosteroids or immunosuppressants must have been administered continuously for 7 days within 14 days prior to the first dose of the study drug;
  5. Received live vaccines (including attenuated live vaccines) within 28 days prior to the study drug administration;
  6. History of or currently having interstitial lung disease/condition requiring systemic corticosteroid treatment;
  7. History of or currently having autoimmune disease;
  8. Presence of other malignant tumors within 5 years prior to the first dose of the study drug;
  9. Presence of uncontrolled comorbidities such as cardiac, renal, gastrointestinal, or infectious diseases;
  10. History of allogeneic bone marrow or organ transplantation;
  11. History of using any antibodies or drugs targeting T-cell co-regulatory proteins (immune checkpoints), or previous treatment with anti-tumor vaccines;
  12. History of hypersensitivity or intolerance to antibody-based drugs, history of any rapid allergic reactions, uncontrolled asthma, or significant drug allergies;
  13. Pregnant and/or breastfeeding women;
  14. Other conditions that may affect the safety or compliance of the study drug, including but not limited to psychiatric disorders, uncontrolled large pleural effusions, or moderate to large pleural effusions requiring repeated drainage.

引自 ClinicalTrials.gov, NCT06528847, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06528847,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06528847